Novartis India Share Price Jumps Up to 10% on 5 October: How a ChrysCapital Takeover, a Rs 860.64 Open Offer Almost Nobody Used and a New Retina Drug Deal Put the Stock at 2.5 Times the Offer Price
- October 5, 2026
- Posted by: Lakshit Sharma
- Category: News
Novartis India up to 10% on 5 Oct, day high Rs 2,164.60. Open offer Rs 860.64 drew only 40 shares. ChrysCapital owns 71%. P/E about 50. Support Rs 1,900.
Quick Answer
Novartis India share price jumped between 7% and nearly 10% on 5 October, reaching an intraday high of Rs 2,164.60, about 2.5 times the Rs 860.64 open offer price that the new ChrysCapital-led owners paid in the takeover. Public shareholders tendered only 40 shares in that offer because the market price was far higher. The company has Rs 668 crore of net cash, a new retina medicine distribution deal and a P/E near 50 on flat revenue of about Rs 354 crore. Analysts say the stock needs to hold above Rs 2,100 for momentum, with support near Rs 1,900.
The Novartis India share price today has become one of the most volatile small caps in the market. It traded near Rs 830 in February, hit a 20% upper circuit at Rs 996.50 when the Swiss parent agreed to sell, and is now above Rs 2,100. On 5 October the stock rose as much as 7.3% to Rs 2,164.60 against a Sensex gain of 0.8%, a stock-specific move on top of the broader market recovery.
If you are searching for what lies ahead for the Novartis India stock, this article covers the ChrysCapital takeover and the Novartis India open offer, the business and its net cash, the Q1 FY27 results, the Accentrix and Pagenax distribution deal and its entry into ophthalmology, valuation, P/E and market capitalisation, the 52-week high, support and key levels, and the risks. Price data is based on NSE and BSE figures, so recheck it before acting.
Click Here – Get Free Investment Predictions
Why Is Novartis India Share Price Jumping Today?
The Novartis India share price is jumping on a mix of a market-wide rebound, a thin free float and a story of private equity ownership. Reports put the gain at 7% to nearly 10%, and the stock traded well above all its key moving averages.
The Novartis India stock was around Rs 2,018 before the rise, and the day’s high of Rs 2,164.60 is about 7% above that. The analyst view in the headline is that the stock must keep above Rs 2,100 to sustain momentum, with support near Rs 1,900.
Novartis India Share Price Timeline: From Takeover to Rs 2,000
| Date | Event | Novartis India share price |
|---|---|---|
| 20 February | Novartis AG agrees to sell its 70.68% stake for about Rs 1,446 crore to a ChrysCapital-led group | Upper circuit at Rs 996.50, up 20% |
| 11 to 24 June | Open offer for 26% at Rs 860.64 per share | Market price far above the offer |
| 29 July | Purchase of the stake closes; Novartis AG ceases to be promoter | Near Rs 1,780 on 23 July |
| 1 September | Stock trades after a long run | Rs 1,582 |
| 8 September | Distribution deal for retina medicines Accentrix and Pagenax | Higher by 22 September |
| 22 September | Trading level | About Rs 2,007 |
| 5 October | Jumps up to 10% | High of Rs 2,164.60 |
From the Rs 830.45 close before the deal to Rs 2,164.60 is a gain of about 160% in under eight months, which is why the Novartis India share price now trades about 2.5 times the open offer price.
ChrysCapital Takeover and the Rs 860.64 Open Offer
| Deal detail | Figure |
|---|---|
| Stake sold by Novartis AG | 70.68% (1,74,50,680 shares) |
| Buyers | Consortium led by WaveRise Investments, ChrysCapital Fund X and Two Infinity Partners |
| Price for the stake | About Rs 1,446 crore; WaveRise paid Rs 860.64 a share, ChrysCapital entities about Rs 701.25 |
| Novartis India open offer | Up to 26% (64,19,608 shares) at Rs 860.64, worth up to Rs 552.49 crore |
| Shares tendered | Only 40 |
| Ownership after the deal (28 August) | ChrysCapital group 71%, retail 26%, institutions 3% |
| Delisting | No intention to delist |
The open offer was priced only 3.64% above the pre-deal close of Rs 830.45. Once the Novartis India share price hit Rs 996.50, no one had a reason to tender, so the acquirers ended up with the 70.68% stake plus almost nothing from the public. The deal implied a value of about Rs 2,046 crore for the whole company, roughly 22 times FY26 profit, and the market capitalisation is now about 2.5 times that.
What Does Novartis India Do?
Novartis India is a pharmaceutical wholesaler and trader. FY26 revenue was about Rs 354 crore, all from wholesale and trading, with no manufacturing or export revenue. Revenue has been flat since FY23, and profit has slipped.
| Financials | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|
| Revenue (Rs crore) | 379 | 335 | 356 | 354 |
| Profit after tax (Rs crore) | 103 | 85 | 101 | 93 |
Q1 FY27 broke the pattern, with revenue up 18.6% to Rs 103.81 crore and net profit up 16.6%, in the first quarter under new management, which supports the Novartis India share price. One quarter is a data point and not a trend.
Check the Univest Screener for live data on pharma stocks
Accentrix and Pagenax: A Retina Deal for the Novartis India Share Price
On 8 September Novartis India agreed an exclusive promotion and distribution deal with Novartis Healthcare Private Limited for the Indian rights to Accentrix (ranibizumab) and Pagenax (brolucizumab), two retina medicines. It pays an upfront Rs 10 crore. The deal marks its entry into ophthalmology and is the first sign of a broader product plan.
The company’s investor presentation talks about building an India-focused pharma platform, with Rs 668 crore of net cash as of March 2026. That is about Rs 270 per share, or roughly 13% of the current price, my calculation, and it gives the new owners room to buy brands or companies, which is the main bull case for the Novartis India share price.
Novartis India Share Price Today: Valuation and Key Numbers
| Item | Figure | What it tells you |
|---|---|---|
| Price, 5 October high | Rs 2,164.60 | About 2.5 times the open offer price |
| Price, 22 September | About Rs 2,007 | Market capitalisation about Rs 4,940 crore |
| Market capitalisation at about Rs 2,100 | About Rs 5,170 crore | Small-cap |
| Trailing P/E | About 50 times | Rich for flat revenue |
| Book value per share | About Rs 331 | Price is about 6 times book |
| Dividend yield | About 1.25% | Small payout |
| 52-week high | About Rs 2,589 (one provider) | Set during the September run |
| Free float | About 29% | Thin, so moves are sharp |
A thin free float explains the violent moves in the Novartis India stock. With only about 29% of shares in public hands, a few buyers can push the Novartis India share price up and a few sellers can drop it just as fast.
Download the Univest iOS App or Univest Android App to track live prices of pharma and small-cap stocks.
Novartis India Share Price Levels to Watch
| Level | Why it matters |
|---|---|
| Rs 2,589 | 52-week high from the September run |
| Rs 2,164.60 | 5 October intraday high |
| Rs 2,100 | Level analysts want held for momentum |
| Rs 2,007 | 22 September trading level |
| Rs 1,900 | Support cited by analysts |
| Rs 1,780 | 23 July high |
| Rs 860.64 | Open offer price |
The Novartis India share price today sits near Rs 2,100 after the Rs 2,164.60 high. These are reference levels for the Novartis India share price, not forecasts.
Risks Behind the Novartis India Share Price
Valuation: At about 50 times earnings and 6 times book, the Novartis India share price already prices a lot of growth.
Flat core business: Revenue was Rs 354 crore in FY26, almost unchanged since FY23, and profit fell about 7%.
Thin float: Only about 29% of shares trade freely, which amplifies both rallies and falls.
Execution risk: The platform plan needs acquisitions or new brands, and none beyond the retina deal is announced.
Momentum reversal: The Novartis India share price has more than doubled since February and rose 160% from the pre-deal close.
What Lies Ahead for the Novartis India Share Price?
- Q2 FY27 results, which will show whether the 18.6% revenue growth continues.
- New product or acquisition announcements from the ChrysCapital-led management.
- Revenue contribution from Accentrix and Pagenax.
- Whether the stock holds Rs 2,100 or falls back toward Rs 1,900.
- Any change in promoter holding or float.
Conclusion
The Novartis India share price rose as much as 10% on 5 October to Rs 2,164.60, roughly 2.5 times the Rs 860.64 open offer that almost nobody used. The business is small and flat, but it has Rs 668 crore of net cash, new owners, a retina drug deal and a thin float. At about 50 times earnings, Rs 2,100 is the level to hold for the Novartis India share price and Rs 1,900 the support to watch. The Novartis India stock is a momentum story. Consult a SEBI-registered advisor before making any decision.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
Frequently Asked Questions
Why did Novartis India share price jump on 5 October?
Ans. The Novartis India share price rose between 7% and nearly 10% on 5 October, hitting Rs 2,164.60 as the market rebounded and momentum built around the ChrysCapital-led ownership and new product plans.
What was the Novartis India open offer price?
Ans. The mandatory open offer was Rs 860.64 per share for up to 26% of the company. Only 40 shares were tendered because the market price was much higher.
Who owns Novartis India now?
Ans. A consortium led by WaveRise Investments, ChrysCapital Fund X and Two Infinity Partners owns about 71%. Novartis AG sold its entire 70.68% stake and is no longer a promoter, so the Novartis India share price now trades on the new owners’ plans.
What does Novartis India do?
Ans. Novartis India is a pharmaceutical wholesaler and trader with about Rs 354 crore of annual revenue. It has no manufacturing or export business.
What is the Accentrix and Pagenax deal?
Ans. On 8 September, Novartis India agreed exclusive promotion and distribution rights in India for two retina medicines, ranibizumab and brolucizumab, for an upfront Rs 10 crore.
What are the key support and resistance levels for Novartis India share price?
Ans. Analysts say the stock must hold above Rs 2,100 for momentum, with support near Rs 1,900. The 5 October high was Rs 2,164.60. These are reference levels and not predictions.
Is Novartis India share price expensive?
Ans. The stock trades at about 50 times earnings and 6 times book value, with revenue flat since FY23. That is rich, and it relies on growth from the new owners.
Is Novartis India a good stock to buy now?
Ans. This article does not constitute investment advice. The Novartis India share price has strong momentum and net cash, but a high valuation and thin float. Consult a SEBI-registered financial advisor before investing.